Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Which game do you cherish observing live? Vote! - 2Without evidence, CDC changes messaging on vaccines and autism
- 3NASA, in a rare move, cuts space station mission short after an astronaut's medical issue
- 4Which Instax Camera Would it be a good idea for you to Purchase?
- 5Dominating the Art of Composing: Creator Bits of knowledge
- The Extraordinary Excursion of Dental Embed Innovation
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- Tech Devices 2023: The Most blazing Arrivals of the Year
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- EU Commission prepares €90bn Ukraine loan despite Hungary's veto
- This Unique National Park In Canada Is Famous For Its Otherworldly Limestone Monoliths
- 'The Housemaid' movie with Sydney Sweeney and Amanda Seyfried premieres this month. What the stars have said about the psychological thriller.
- Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- Iranian naval commander Alireza Tangsiri killed in attack, says Israel
